skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index
Refined by: Database: Lirias (KU Leuven Association) remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin
Material Type:
Article 		Add to My Research

Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin

GASTROENTEROLOGY, 2019-09, Vol.157 (3), p.682-+ [Peer Reviewed Journal]

ISSN: 0016-5085 ;EISSN: 1528-0012

Digital Resources/Online E-Resources

Citations Cited by
2
Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial
Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial
Material Type:
Article 		Add to My Research

Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial

GASTROENTEROLOGY, 2019-08, Vol.157 (2), p.403-+ [Peer Reviewed Journal]

ISSN: 0016-5085 ;EISSN: 1528-0012

Digital Resources/Online E-Resources

Citations Cited by
3
Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial
Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial
Material Type:
Article 		Add to My Research

Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2022-12, Vol.8 (8), p.786-795 [Peer Reviewed Journal]

ISSN: 2055-6837 ;EISSN: 2055-6845

Full text available

Citations Cited by
4
Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial
Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial
Material Type:
Article 		Add to My Research

Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial

Canadian Journal of Cardiology, 2017, Vol.33 (8), p.1027-1035 [Peer Reviewed Journal]

ISSN: 0828-282X ;EISSN: 1916-7075

Digital Resources/Online E-Resources

Citations Cited by

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To
Refine
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait